The antithrombotic effects of bovine activated protein C (APC) and protein S were investigated in a rabbit model of microarterial thrombosis. Because of the species specificity of the APC-protein S interaction, bovine APC expresses potent anticoagulant activity in rabbit plasma only when bovine protein S is also present. This provided a way to assess the contribution of bovine protein S to the antithrombotic effect of bovine APC. Rabbits were infused with boluses of activated protein C (0.1, 0.2, 0.4, or 0.8 mg/kg), protein S (0.5 mg/kg), or activated protein C (0.1 or 0.01 mg/kg) plus protein S (0.5 mg/kg). APC alone produced a dose-dependent antithrombotic effect, but only the group receiving the highest dose differed signiflcantly from controls. While a low dose of activated protein C (0.1 mg/kg) alone had no antithrombotic effect, together with protein S (0.5 mg/kg) it produced a potent response. The presented results demonstrate the in vivo significance of protein S as a cofactor to activated protein C. The data show that a potent antithrombotic effect, without hemorrhagic side effects or significant systemic anticoagulation, may be achieved by low doses of activated protein C when combined with protein S. (J.
Introduction
The self-amplifying cascade of blood coagulation constitutes a potential danger to the organism, and several control systems are operative to dampen its actions. One of these systems is the protein C anticoagulant system, which provides a powerful mechanism for limitation of thrombus formation and propagation in vivo (reviewed in 1). The key components of the protein C anticoagulant system are the vitamin K-dependent proteins C and S and the endothelial cell membrane protein thrombomo- dulin. Protein C circulates as zymogen of a serine protease and is converted to its active form by thrombin bound to thrombomodulin. Activated protein C (APC)' selectively degrades the activated forms of coagulation cofactors V and VIII, thereby counteracting the positive feedback actions of thrombin on the coagulation cascade. This process is potentiated by the vitamin K-dependent protein S. In human plasma, protein S forms a complex with C4b-binding protein (C4BP), which is a regulator of the classical complement pathway (reviewed in 1, 2). Only free protein S acts as a cofactor to APC, whereas the complexed form, which accounts for -60% of total protein S in human plasma, has no anticoagulant cofactor activity (3) (4) (5) . Rabbit plasma only contains free protein S, which, however, is readily complexed with human C4BP (6, 7) . Recently, another cofactor to APC was proposed (8) and subsequently identified as the nonactivated form of Factor V (9, 10) . The biological significance of the endogenous anticoagulant protein C system is best illustrated by the massive neonatal thrombotic events that accompany homozygous deficiency of either protein C or protein S ( 11) and the milder thrombophilia that is associated with heterozygous deficiencies ( 12) . Moreover, it has recently been shown that resistance to the anticoagulant function of APC, due to a single point mutation in the gene for Factor V, is a major risk factor for thrombosis (8, 9, (13) (14) (15) (16) (17) (18) (19) (20) .
Because of its specific anticoagulant activity and its endogenous origin, APC is potentially highly interesting as an antithrombotic agent. The antithrombotic features of APC have been demonstrated in different animal studies. Thus, human APC blocks the lethal effects of Escherichia coli endotoxin shock in baboons (21) , reduces jugular vein thrombus formation in dogs (22) , delays anodal current-induced aorta thrombus formation in rats (23) , and reduces intermittent platelet thrombus formation in rat microvessels (24) . Human APC is also an effective antithrombotic agent in a hypertraumatic arteriovenous graft model in baboons, when infused in close proximity to the trauma area (25, 26 ). An antithrombotic effect of thrombin-generated endogenous APC has also been demonstrated in the same model (27) . Using bovine material, Emekli et al. demonstrated in an early study that APC blocks disseminated intravascular coagulation in rabbits (28) . Recently, we have shown that a high intravenous bolus of bovine APC effectively prevents thrombosis in a highly traumatic microarterial model in rabbits (29) .
Although previous work has demonstrated the importance of protein S in tuning down combined inflammatory and coagulopathic responses in states of experimental E. coli-induced disseminated intravascular coagulation (30) , the in vivo role of protein S as a cofactor to APC is essentially unknown. In fact, the importance of the APC cofactor function of protein S has been debated, because the cofactor activity is quite weak in in vitro systems, and, in addition, it has been suggested that protein S also has anticoagulant properties independent of APC (31) (32) (33) . Protein S increases the proteolytic activity of APC twofold, and, in addition, it inhibits the protection of Factors Vlla and Va against APC-mediated degradation that Factors IXa and Xa, respectively, provide (32, 34) . Protein S is known to increase the affinity of APC for negatively charged phospholipids where enzyme and cofactor seem to form a 1:1 stoichiometric complex (35, 36) . Since thrombus formation is a process largely taking place on activated membrane surfaces, a key function of protein S in vivo may be to target APC to sites of evolving thrombi.
The APC cofactor function of protein S is species specific (37) , which provides an experimental tool for specifically studying the importance of protein S in vivo. The present study was undertaken to characterize the antithrombotic potential of APC and protein S in a rabbit model of microarterial thrombosis, using bovine protein components. We report that APC has an antithrombotic effect in this animal model and that the APC cofactor activity of protein S is important in vivo for expression of full antithrombotic activity of APC.
Methods
Thrombosis model. Swedish loop rabbits of either sex, weighing 2.5-3.5 kg (mean 3.0 kg), were anesthetized with intravenous pentobarbital. A detailed description of the experimental procedure has been given elsewhere (29) . Briefly, 3-cm-long segments of the central arteries of both ears (outer diameter -1 mm) were prepared. Blood flow was interrupted, and 7-mm artery segments were isolated between vascular clamps. 7-mm-long arteriotomies were performed, vascular lumina were everted and flattened, and 5 mm of vascular lumina was denuded with a scalpel blade, thereby exposing deep layers of the tunica media (38) . The arteriotomies were closed with continuous sutures. After reperfusion (opening of the vascular clamps), arteriotomy bleeding times were recorded. Vessel patency was assessed at 30 and 120 min after reperfusion using a standard microsurgical empty/refill test (29, 39) . In this test, the vessels were occluded distal to the trauma area using a pair of microforceps and gently emptied downstream with another pair of forceps. The first pair of forceps was then released, and the vessel refilling was assessed, classing the vessels as patent or occluded. Occluded vessels showed no refilling, while patent vessels showed rapid or slow refilling, the latter being referred to as "reduced patency." After the final patency test, the thrombotic material was removed and weighed. The animals were killed by injection of concentrated sodium pentobarbital and alcohol.
Proteins. Bovine protein C was purified and activated as described previously (29, 40) . The protein was > 95% pure, as judged by PAGE run in the presence of SDS before and after reduction of disulphide bonds. In the presence of bovine protein S. bovine APC (0.5-1 /.g/ ml) prolonged the activated partial thromboplastin time (APTT) of human plasma two-to threefold (29) . In the absence of bovine protein S, bovine APC had little effect on the clotting of human plasma, which is in agreement with results on record (37) . The effects of bovine APC, with and without added bovine protein S, in a rabbit plasma system have been previously shown (6, 29) . Bovine protein S and human C4BP (devoid of protein S) were purified as described previously (41, 42 Tris-HCl, 0.15 M NaCl, pH 7.5, containing 1 mg/ml BSA). A separate group of rabbits receiving 0.8 mg/kg APC were given boluses of human C4BP (4 mg/kg) 15 min before administration of APC. In a subsequent study (referred to as the protein S study), five groups of rabbits were treated with either 0.1 mg/kg APC, 0.5 mg/kg protein S, 0.1 mg/kg APC + 0.5 mg/kg protein S, 0.01 mg/kg APC + 0.5 mg/kg protein S, or vehicle. The number of rabbits in each experimental group was 10, and, since both ears were used in each rabbit, data from 20 vessels were obtained in each group, except for the vehicle and 0.8 mg/kg APC groups in the dose-response study and the 0.1 mg/kg APC group in the protein S study, where the number of observations was 19 for technical reasons. Throughout, the animals were treated in a blind random fashion, except for the C4BP group in the dose-response study, which was added as a separate group after completion of the randomized series. APC, protein S, or their combinations were given as intravenous bolus injections 5 min before vascular reperfusion. Different batches of APC were used in the dose-response study and in the protein S study.
Plasma levels ofinfused proteins. The levels of infused bovine APC and protein S in rabbit plasma were assessed with ELISA assays, using citrated plasma sampled as described above. 50 jl/well) were incubated at room temperature for 2 h, after which the wells were washed three times. Rabbit peroxidase-conjugated antimouse antibodies (DAKO; Dakopatts A/S, Glostrup, Denmark) (diluted 1/1,000 in TBS, 0.1% BSA, 2 mM CaCl2, 50 jl/well) were added, and the plates were incubated for 1 h, after which the wells were washed three times. 200 jil of the substrate 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfuronic acid) (ABTS; Sigma Chemical Co., St.
Louis, MO) was added to each well and the absorbance was measured at 405 nm.
Estimates ofendogenous (rabbit) levels ofproteins C and S. Rabbit protein C plasma concentration was estimated using a commercial kit for detection of protein C activity in human plasma (Coamatic Protein C; Chromogenix). The assay involves activation of protein C by snake venom and determination of the rate of hydrolysis of the chromogenic substrate S-2366 measured at 405 nm in an automatic analyzer (Cobas Mira, Roche, Basel, Switzerland). A dilution curve obtained with citrated rabbit plasma (sampled as above) was closely parallel to the standard curve for human plasma, and therefore rabbit plasma samples were read against the human standard curve. Rabbit protein S levels were estimated by a clotting assay that measured inhibition of human APC cofactor function in rabbit plasma by human C4BP and was performed essentially as described elsewhere (6) . Increasing amounts of purified human C4BP were added to rabbit plasma (final concentrations 0-200 ,g/ml) and incubated for 2 h at 37°C. The rabbit plasma (100 j1i) was then incubated with 100 ul of AP1T reagent (PTT automate; Diagnostica Stago, Asnieres, France) for 5 min at 37°C, after which 100 p1 of 30 mM calcium chloride containing human APC (final concentration 0.5 ,ug/ml) was added and the clotting time measured with an Amelung Coagulometer KC 10 (Heinrich Amelung GmbH, Lieme, Germany). The molar concentration of protein S in rabbit plasma was assumed to be equal to the lowest concentration of C4BP that still gave full inhibition of APC cofactor function. Hemostatic parameters. Analyses of APTT and platelet counts were performed essentially as described (29) . Blood for APTT analyses was drawn just before and at 10, 60, and 120 min after administration of the substances. In animals pretreated with C4BP, samples were also drawn after the administration of C4BP but immediately before infusion of APC. The samples (nine parts blood, one part 3.85% sodium citrate) were centrifuged for 15 min at 5,000 rpm and frozen directly at -70'C. APTT was analyzed immediately after thawing. Blood samples for platelet counts were drawn just before and 60 min after APC administration (in animals pretreated with C4BP, preinfusion samples were drawn before the infusion of C4BP, and postinfusion samples 75 min later). Platelets were counted in Technicon Hi (Technicon Instrument, Tarrytown, NY) or STKS automatic analyzers (Coulter Corp., Hialeah, FL) or in a minority of cases in a Burker's chamber (Poly-Optik GmbH, Bad Blankenburg, Germany).
Statistical methods. StatXact (CYTEL Software Corporation; Cambridge, MA) was used for statistical calculations. Pairwise observations were obtained from each animal, and statistical comparisons were therefore based on the assumption that the observations were interdependent. Mean values for arteriotomy bleeding times and thrombus weights were calculated for each animal, and groups were compared using the MannWhitney U test. Patency in each animal was coded as 0, 1, or 2 depending on the number of patent vessels, and the Jonckheere-Terpstra test (44) was used for comparison between the groups. Two-sided P values are given, and medians and percentiles are shown. P values < 0.05 were regarded as statistically significant.
Results
Plasma levels of endogenous and infused proteins. Using a chromogenic functional assay, the concentration of protein C in rabbit plasma was estimated to be -80% (mean of 10 observations) of that of protein C in human plasma (3) (4) (5) ug/ml). The concentration of protein S in rabbit plasma was estimated from the ability of human C4BP to dose-dependently inhibit the APC cofactor function in rabbit plasma. The This is distinctly lower than the concentration of free protein S in human plasma (10 jig/ml). The highest bolus (0.8 mg/kg) of bovine APC gave median concentrations in rabbit plasma of 9.5 tzg/ml (Fig. 1) , which was more than three times the endogenous protein C concentration. The 0.4-mg/ml dose produced plasma levels comparable to the physiological protein C levels, and the 0.1-mg/kg dose yielded concentrations below the physiological protein C levels. The plasma concentrations of bovine protein S after the 0.5-mg/kg bolus dose peaked at 13.2 1zg/ml (median value) and were more sustained in time than the APC levels. Antithrombotic effects. In the dose-response study, only the highest APC dose (0.8 mg/kg) produced a powerful antithrombotic effect, which was evident both in assessment of patency rates at 30 and 120 min after reperfusion (Fig. 2) , and in measurements of thrombus weights (Fig. 3) . However, a significant Antihemostatic effects. The highest dose of APC produced a mild hemostatic defect, as detected by prolonged bleeding times, and a significant dose-dependent effect was observed when comparison was made between the three APC groups (Fig. 4) . In the protein S study, no significant effects on hemostasis were noted by the combination of APC (0.1 mg/kg) and protein S. (0.1-0.4 mg/kg) did not yield any measurable effect, or only modestly prolonged the APTJ, the highest dose (0.8 mg/kg) produced a distinct APTT prolongation (Fig. 5) . Median values of APC-induced APTT prolongation were maximally 2.2 times the baseline at 10 min after reperfusion. The anticoagulant response in the 0.8-mg/kg group showed great interindividual variation, in particular shortly after injection. Pretreatment with C4BP resulted in a decrease in the APTI prolongations seen after APC infusion. C4BP alone did not alter the baseline APTT values. In the protein S study, a notable feature was that, in contrast to the potent antithrombotic response produced by APC (0.1 mg/kg) + protein S (0.5 mg/kg), the anticoagulant response was mild, APTT prolongation being maximally 1.3 times the baseline. Protein S alone did not affect the APTT. Platelet counts. Numbers of circulating platelets remained essentially unchanged in all groups except for the group infused with human C4BP, which showed a distinct drop in platelet count, median platelet count at 75 min after infusion being 57% of preinfusion values.
Discussion
This study for the first time shows the significance of protein S as a cofactor to activated protein C in vivo by demonstrating potentiation of the antithrombotic effect of APC in a model of experimental thrombosis. In the model used, the effects of a multitude of antithrombotic agents have been described (45) (46) (47) (48) (49) (50) (51) . Since surgical repair of the vessels is involved, hemostatic side effects of given agents may be assessed, as demonstrated by previous studies (29, 49) .
The APC cofactor function of protein S demonstrates species specificity (5, 37) . Depending on the experimental condi- tions, the ability of rabbit protein S to potentiate the anticoagulant response to bovine APC has been found to be almost nil (37) or relatively low (6 
